News & Updates

Show Multimedia Only

Rifaximin prevents post-TIPS overt hepatic encephalopathy

06 Jul 2021

Use of rifaximin is well tolerated and lowers the risk of overt hepatic encephalopathy in patients with cirrhosis treated with transjugular intrahepatic portosystemic shunt (TIPS), a recent study has shown.

Rifaximin prevents post-TIPS overt hepatic encephalopathy

06 Jul 2021

Certain signs, symptoms in early dengue may predict disease progression

05 Jul 2021 by

Certain signs such as low platelet counts and serum albumin levels, and symptoms like vomiting and abdominal pain during the early, febrile phase of dengue may predict progression to severe disease, according to a systematic review and meta-analysis.

Certain signs, symptoms in early dengue may predict disease progression

05 Jul 2021

Hepatic arterial infusion chemo outdoes sorafenib for advanced liver cancer

02 Jul 2021 by

Hepatic arterial infusion chemotherapy consisting of a FOLFOX* regimen (HAIC-FO) showed superior efficacy over sorafenib in the first-line treatment of locally advanced or unresectable hepatocellular carcinoma (HCC), according to the findings of the phase III FOHAIC-1 study presented at ASCO 2021.

Hepatic arterial infusion chemo outdoes sorafenib for advanced liver cancer

02 Jul 2021

News & Updates

Showing Hepatology articles

Showing

Specialty:

Rifaximin prevents post-TIPS overt hepatic encephalopathy

Rifaximin prevents post-TIPS overt hepatic encephalopathy

Certain signs, symptoms in early dengue may predict disease progression

Certain signs, symptoms in early dengue may predict disease progression

Hepatic arterial infusion chemo outdoes sorafenib for advanced liver cancer

Hepatic arterial infusion chemo outdoes sorafenib for advanced liver cancer